$ELAN
Elanco Animal Health Inc Stock $elan

$elan Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000173910420000008 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$658.0M	$731.1M
YoY Change	-10.0%	-0.69%
Cost Of Revenue	$333.0M	$343.8M
YoY Change	-3.14%	-4.5%
Gross Profit	$325.0M	$387.3M
YoY Change	-16.09%	2.95%
Gross Profit Margin	49.39%	52.97%
Selling, General & Admin	$182.0M	$181.1M
YoY Change	0.5%	0.61%
% of Gross Profit	56.0%	46.76%
Research & Development	$67.00M	$64.10M
YoY Change	4.52%	-1.69%
% of Gross Profit	20.62%	16.55%
Depreciation & Amortization	$82.00M	$75.20M
YoY Change	9.04%	1.21%
% of Gross Profit	25.23%	19.42%
Operating Expenses	$249.0M	$245.2M
YoY Change	1.55%	0.0%
Operating Profit	$76.00M	$142.1M
YoY Change	-46.52%	8.47%
Interest Expense	$16.00M	$20.80M
YoY Change	-23.08%
% of Operating Profit	21.05%	14.64%
Other Income/Expense, Net	-$1.000M	-$2.600M
YoY Change	-61.54%	36.84%
Pretax Income	-$68.00M	$44.80M
YoY Change	-251.79%	-42.19%
Income Tax	-$19.00M	$13.30M
% Of Pretax Income		29.69%
Net Earnings	-$49.00M	$31.50M
YoY Change	-255.56%	-56.67%
Net Earnings / Revenue	-7.45%	4.31%
Basic Earnings Per Share	-$0.12	$0.09
Diluted Earnings Per Share	-$0.12	$0.09
COMMON SHARES
Basic Shares Outstanding	403.9M shares	365.7M shares
Diluted Shares Outstanding	403.9M shares	366.0M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.206B	$272.0M
YoY Change	343.38%
Cash & Equivalents	$1.206B	$272.1M
Short-Term Investments
Other Short-Term Assets	$143.0M	$144.0M
YoY Change	-0.69%
Inventory	$1.019B	$1.036B
Prepaid Expenses
Receivables	$676.8M	$684.1M
Other Receivables	$66.90M	$107.8M
Total Short-Term Assets	$3.121B	$2.278B
YoY Change	36.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$930.1M	$930.2M
YoY Change	-0.01%
Goodwill	$3.004B	$2.933B
YoY Change	2.42%
Intangibles	$2.456B	$2.387B
YoY Change	2.89%
Long-Term Investments	$20.00M	$15.70M
YoY Change	27.39%
Other Assets	$217.0M	$219.3M
YoY Change	-1.05%
Total Long-Term Assets	$6.607B	$6.469B
YoY Change	2.13%
TOTAL ASSETS
Total Short-Term Assets	$3.121B	$2.278B
Total Long-Term Assets	$6.607B	$6.469B
Total Assets	$9.727B	$8.747B
YoY Change	11.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$215.0M	$252.1M
YoY Change	-14.72%
Accrued Expenses	$56.00M	$86.00M
YoY Change	-34.88%
Deferred Revenue	$192.7M	$171.7M
YoY Change	12.23%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$26.00M	$29.00M
YoY Change	-10.34%
Total Short-Term Liabilities	$707.5M	$708.2M
YoY Change	-0.1%
LONG-TERM LIABILITIES
Long-Term Debt	$2.036B	$2.437B
YoY Change	-16.46%
Other Long-Term Liabilities	$150.3M	$168.4M
YoY Change	-10.75%
Total Long-Term Liabilities	$2.186B	$2.605B
YoY Change	-16.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$707.5M	$708.2M
Total Long-Term Liabilities	$2.186B	$2.605B
Total Liabilities	$3.066B	$3.551B
YoY Change	-13.67%
SHAREHOLDERS EQUITY
Retained Earnings	$33.80M	$47.90M
YoY Change	-29.44%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.661B	$5.196B
YoY Change
Total Liabilities & Shareholders Equity	$9.727B	$8.747B
YoY Change	11.2%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$49.00M	$31.50M
YoY Change	-255.56%	-56.67%
Depreciation, Depletion And Amortization	$82.00M	$75.20M
YoY Change	9.04%	1.21%
Cash From Operating Activities	$4.000M	$8.100M
YoY Change	-50.62%	-82.77%
INVESTING ACTIVITIES
Capital Expenditures	$13.00M	$28.00M
YoY Change	-53.57%	-14.37%
Acquisitions	$0.00
YoY Change
Other Investing Activities	$0.00	$500.0K
YoY Change	-100.0%	-70.59%
Cash From Investing Activities	-$20.00M	-$31.00M
YoY Change	-35.48%	-9.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$897.0M	-$339.5M
YoY Change	-364.21%	343.79%
NET CHANGE
Cash From Operating Activities	$4.000M	$8.100M
Cash From Investing Activities	-$20.00M	-$31.00M
Cash From Financing Activities	$897.0M	-$339.5M
Net Change In Cash	$872.0M	-$376.9M
YoY Change	-331.36%	528.17%
FREE CASH FLOW
Cash From Operating Activities	$4.000M	$8.100M
Capital Expenditures	$13.00M	$28.00M
Free Cash Flow	-$9.000M	-$19.90M
YoY Change	-54.77%	-239.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001739104
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-38661
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Elanco Animal Health Inc
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5497352
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2500 INNOVATION WAY
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	GREENFIELD
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46140
CY2020Q1	dei	City Area Code CityAreaCode	877
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	352-6261
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	398894363	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	657700000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	731100000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	332700000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	343800000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66800000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64100000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	182000000.0	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	181100000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51600000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000000.0	USD
CY2020Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	74800000	USD
CY2019Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	24900000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	16500000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	20800000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1100000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2600000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	725500000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	686300000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-67800000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	44800000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18700000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13300000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31500000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	403900000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	365700000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	403900000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	366000000.0	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-49100000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31500000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-39200000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-29300000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30200000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	400000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-2000000.0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-68900000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28200000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-118000000.0	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3300000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1206400000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	334000000.0	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7400000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6200000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	676800000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	816900000	USD
CY2020Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	66900000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	73000000.0	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	1019000000.0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1050700000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	132100000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	87400000	USD
CY2020Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	8700000	USD
CY2019Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	10700000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11100000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	3120600000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	2373100000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	3004000000.0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2989600000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2455500000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2482800000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	217000000.0	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000000.0	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	919700000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	930500000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	930100000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	955300000	USD
CY2020Q1	us-gaap	Assets Assets	9727200000	USD
CY2019Q4	us-gaap	Assets Assets	8985800000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	215000000.0	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	222600000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	56200000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	99600000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	192700000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	211000000.0	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	26000000.0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	24500000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	217600000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	244400000	USD
CY2020Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	16400000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	707500000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	818500000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2035600000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2330500000	USD
CY2020Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	82100000	USD
CY2019Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	82500000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	90200000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	100800000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150300000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106600000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	3065700000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	3438900000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	398825969	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	398825969	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	373011513	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	373011513	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6870300000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5636300000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	33800000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	84300000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-242600000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-173700000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	6661500000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	5546900000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9727200000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8985800000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	5197500000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31500000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28200000	USD
CY2019Q1	elan	Stockholders Equity Separation Adjustments StockholdersEquitySeparationAdjustments	-7000000.0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2400000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	5196200000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	5546900000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-49100000	USD
CY2020Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1400000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-68900000	USD
CY2020Q1	elan	Stockholders Equity Separation Adjustments StockholdersEquitySeparationAdjustments	15800000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11100000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	-12800000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	767500000	USD
CY2020Q1	elan	Tangible Equity Units Issued During Period Value TangibleEquityUnitsIssuedDuringPeriodValue	452400000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	6661500000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-49100000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31500000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	81500000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	75200000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25100000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	16300000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11100000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7700000	USD
CY2020Q1	elan	Asset Impairment Charges Including Inventory Write Down AssetImpairmentChargesIncludingInventoryWriteDown	0	USD
CY2019Q1	elan	Asset Impairment Charges Including Inventory Write Down AssetImpairmentChargesIncludingInventoryWriteDown	4000000.0	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3800000	USD
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2020Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	9800000	USD
CY2019Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	117200000	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-500000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-9400000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4300000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8100000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12600000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000000.0	USD
CY2020Q1	us-gaap	Proceeds From Hedge Investing Activities ProceedsFromHedgeInvestingActivities	25200000	USD
CY2019Q1	us-gaap	Proceeds From Hedge Investing Activities ProceedsFromHedgeInvestingActivities	0	USD
CY2020Q1	us-gaap	Payments For Software PaymentsForSoftware	31800000	USD
CY2019Q1	us-gaap	Payments For Software PaymentsForSoftware	2500000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	400000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	500000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19600000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000000.0	USD
CY2020Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	371400000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	7500000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	79200000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1219900000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3100000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020Q1	elan	Payments Of Separation Related Costs Financing Activities PaymentsOfSeparationRelatedCostsFinancingActivities	0	USD
CY2019Q1	elan	Payments Of Separation Related Costs Financing Activities PaymentsOfSeparationRelatedCostsFinancingActivities	175100000	USD
CY2020Q1	elan	Proceeds From Payments To Transactions With Parent ProceedsFromPaymentsToTransactionsWithParent	-15200000	USD
CY2019Q1	elan	Proceeds From Payments To Transactions With Parent ProceedsFromPaymentsToTransactionsWithParent	-156400000	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-12800000	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-500000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	896600000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-339500000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9300000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14500000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	872000000.0	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-376900000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345100000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	677500000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1217100000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300600000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1206400000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272100000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	10700000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	28500000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1217100000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300600000	USD
CY2020Q1	elan	Number Of Brands In Entitys Portfolio NumberOfBrandsInEntitysPortfolio	125	brand
CY2020Q1	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	90	country
CY2020Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 2. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated. </span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.</span></div><div style="text-indent:9pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. </span></div>The significant accounting policies set forth in Note 4 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standards that were effective January 1, 2020 as described in Note 4: Implementation of New Financial Accounting Pronouncements, and are incorporated herein by reference.
CY2020Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150400000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	118500000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	60500000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	65700000	USD
CY2020Q1	elan	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	73300000	USD
CY2019Q1	elan	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	64200000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	137600000	USD
CY2019Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	120000000.0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	657700000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	731100000	USD
CY2019Q3	elan	Business Combination Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration BusinessCombinationVolumeWeightedAverageStockPriceAsOfLastDayOfTradingBeforeClosingAcquisitionDuration	P20Y
CY2019Q3	elan	Business Combination Volume Weighted Average Price For30 Trading Days BusinessCombinationVolumeWeightedAveragePriceFor30TradingDays	33.60
CY2020Q1	elan	Number Of Divestitures NumberOfDivestitures	3	numberOfDivestitures
CY2020Q1	us-gaap	Severance Costs1 SeveranceCosts1	400000	USD
CY2019Q1	us-gaap	Severance Costs1 SeveranceCosts1	500000	USD
CY2020Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	600000	USD
CY2019Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	USD
CY2020Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	76300000	USD
CY2019Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	20400000	USD
CY2020Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2019Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	4000000.0	USD
CY2020Q1	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	1300000	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	0	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	3800000	USD
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2020Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	74800000	USD
CY2019Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	24900000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	44400000	USD
CY2019Q1	us-gaap	Restructuring Charges RestructuringCharges	500000	USD
CY2019Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	7600000	USD
CY2019Q1	us-gaap	Restructuring Reserve RestructuringReserve	37300000	USD
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	20900000	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	1600000	USD
CY2020Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-600000	USD
CY2020Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	10800000	USD
CY2020Q1	us-gaap	Restructuring Reserve RestructuringReserve	11100000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	384200000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	402900000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	592100000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	603200000	USD
CY2020Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	80700000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	83900000	USD
CY2020Q1	us-gaap	Inventory Gross InventoryGross	1057000000.0	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	1090000000.0	USD
CY2020Q1	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	38000000.0	USD
CY2019Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	39300000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	1019000000.0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1050700000	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	25000000.0	shares
CY2020Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	767500000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	17900000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	16800000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	2061600000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	2355000000.0	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	26000000.0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	24500000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2035600000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2330500000	USD
CY2020Q1	us-gaap	Equity Method Investments EquityMethodInvestments	20000000.0	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	18800000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-39200000	USD
CY2019Q4	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-11400000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18700000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13300000	USD
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.276
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.297
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18700000	USD
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.276
CY2020Q1	elan	Discrete Income Tax Benefit DiscreteIncomeTaxBenefit	-1900000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13300000	USD
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.297
CY2020Q1	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	657700000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	731100000	USD
CY2020Q1	us-gaap	Noncurrent Assets NoncurrentAssets	1147400000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	1147100000	USD
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	300000	shares
CY2020Q1	elan	Proceeds From Payments To Transactions With Parent ProceedsFromPaymentsToTransactionsWithParent	-15200000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	10700000	USD

Files In Submission

Name	View Source	Status
0001739104-20-000008-index-headers.html	Edgar Link	pending
0001739104-20-000008-index.html	Edgar Link	pending
0001739104-20-000008.txt	Edgar Link	pending
0001739104-20-000008-xbrl.zip	Edgar Link	pending
elan-20200331.htm	Edgar Link	pending
elan-20200331.xsd	Edgar Link	pending
elan-20200331_cal.xml	Edgar Link	unprocessable
elan-20200331_def.xml	Edgar Link	unprocessable
elan-20200331_htm.xml	Edgar Link	completed
elan-20200331_lab.xml	Edgar Link	unprocessable
elan-20200331_pre.xml	Edgar Link	unprocessable
ex101elanco-20200331xo.htm	Edgar Link	pending
ex102elanco-20200331xp.htm	Edgar Link	pending
ex103elanco-20200331xc.htm	Edgar Link	pending
ex104elanco-20200331xs.htm	Edgar Link	pending
ex311elanco-20200331xc.htm	Edgar Link	pending
ex312elanco-20200331xc.htm	Edgar Link	pending
ex32elanco-20200331xse.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image11.jpg	Edgar Link	pending
image111.jpg	Edgar Link	pending
image21.jpg	Edgar Link	pending
image211.jpg	Edgar Link	pending
image212.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELAN
Elanco Animal Health Inc Stock $elan

2020 Q1 Form 10-Q Financial Statement

#000173910420000008 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAN Elanco Animal Health Inc Stock $elan

2020 Q1 Form 10-Q Financial Statement

#000173910420000008 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAN
Elanco Animal Health Inc Stock $elan